诺思格(301333)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

301333 诺思格

已收盘 05-17 15:00:00

{"stockData":{"symbol":"301333","market":"SZ","secType":"STK","nameCN":"诺思格","latestPrice":43.77,"timestamp":1715929404000,"preClose":44.18,"halted":0,"volume":1035780,"delay":0,"floatShares":56731200,"shares":96000000,"eps":1.6333,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.41,"latestTime":"05-17 15:00:00","open":44.17,"high":44.46,"low":43.33,"amount":45280400,"amplitude":0.0256,"askPrice":43.78,"askSize":2,"bidPrice":43.77,"bidSize":1,"shortable":0,"etf":0,"ttmEps":1.6333,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1716168600000},"adr":0,"adjPreClose":44.18,"symbolType":"stock","openAndCloseTimeList":[[1715909400000,1715916600000],[1715922000000,1715929200000]],"highLimit":48.6,"lowLimit":39.76,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":96000000,"pbRate":2.39,"roa":"--","roe":"1.31%","epsLYR":2.08,"committee":0.802469,"marketValue":4202000000,"floatMarketCap":2483000000,"peRate":26.798507,"changeRate":-0.0093,"turnoverRate":0.0183,"status":1},"requestUrl":"/m/hq/s/301333","defaultTab":"news","newsList":[{"id":"2435785621","title":"诺思格：公司在美业务主要为数据管理与统计分析服务，现阶段生物法案对公司在美国的业务没有影响","url":"https://stock-news.laohu8.com/highlight/detail?id=2435785621","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2435785621?lang=zh_cn&edition=full","pubTime":"2024-05-16 17:01","pubTimestamp":1715850118,"startTime":"0","endTime":"0","summary":"证券之星消息，诺思格(301333)05月16日在投资者关系平台上答复投资者关心的问题。投资者：董秘你好！生物法案影响贵司在美国的业务吗？如没响应，贵司如何考虑尽可能去拿到美国市场订单，谢谢！诺思格董秘：尊敬的投资者您好！公司在美业务主要为数据管理与统计分析服务，现阶段生物法案对公司在美国的业务没有影响。感谢您的关注！以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051600025551.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431883744","title":"4月29日诺思格涨6.34%，广发聚丰混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431883744","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431883744?lang=zh_cn&edition=full","pubTime":"2024-04-29 16:45","pubTimestamp":1714380358,"startTime":"0","endTime":"0","summary":"证券之星消息，4月29日诺思格涨6.34%，收盘报48.81元，换手率4.5%，成交量2.55万手，成交额1.24亿元。根据2024基金Q1季报公募基金重仓股数据，重仓该股的公募基金共8家，其中持有数量最多的公募基金为广发聚丰混合A。广发聚丰混合A目前规模为22.56亿元，最新净值0.531，较上一交易日上涨2.02%，近一年下跌30.16%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900017820.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2431988308","title":"诺思格涨6.34%，开源证券五日前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2431988308","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2431988308?lang=zh_cn&edition=full","pubTime":"2024-04-29 16:45","pubTimestamp":1714380354,"startTime":"0","endTime":"0","summary":"今日诺思格涨6.34%，收盘报48.81元。2024年4月24日，开源证券研究员余汝意,汪晋发布了对诺思格的研报《公司信息更新报告：收入端稳健增长，利润端受股份支付影响短期承压》，该研报对诺思格给出“买入”评级。鉴于2023年新签合同金额增速稳健，为未来业绩稳健增长提供保障，维持“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为72.39%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900017812.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429643799","title":"诺思格：2024年1月公司收购上海衡领医药科技有限公司","url":"https://stock-news.laohu8.com/highlight/detail?id=2429643799","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429643799?lang=zh_cn&edition=full","pubTime":"2024-04-24 20:01","pubTimestamp":1713960060,"startTime":"0","endTime":"0","summary":"2024年1月公司收购上海衡领医药科技有限公司。上海衡领医药科技有限公司于2019年10月成立，专注于创新药物体内外药物代谢动力学评价服务。另外，公司2023年限制性股票激励计划将于2024年第一至三季度每季度分别摊销1,303.50万元，第四季度摊销639.86万元，全年合计摊销4,550.36万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042400042236.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429152290","title":"诺思格获信达证券买入评级，盈利能力提升+订单持续增长助力长远发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2429152290","media":"金融界","top":-1,"share":"https://www.laohu8.com/m/news/2429152290?lang=zh_cn&edition=full","pubTime":"2024-04-23 15:54","pubTimestamp":1713858874,"startTime":"0","endTime":"0","summary":"4月23日，诺思格获信达证券买入评级，近一个月诺思格获得1份研报关注。研报预计2024-2026年公司营业收入为8.66/10.39/12.61亿元，同比增长20.04%/20.01%/21.33%；归母净利润分别为1.85/2.09/2.61亿元，同比增长13.74%/13.24%/24.54%，对应2024-2026年PE分别为23/20/16倍。聚焦临床试验CRO领域，核心业务稳健增长。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231554378b499d7f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202404231554378b499d7f&s=b","is_publish_highlight":false,"gpt_icon":0},{"id":"2429027179","title":"诺思格（301333）2024年一季报简析：增收不增利，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2429027179","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429027179?lang=zh_cn&edition=full","pubTime":"2024-04-23 06:10","pubTimestamp":1713823844,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期诺思格发布2024年一季报。根据财报显示，本报告期中诺思格增收不增利，三费占比上升明显。截至本报告期末，公司营业总收入1.77亿元，同比上升10.19%，归母净利润2304.89万元，同比下降19.95%。2024年诺思格将依托丰富的经验寻找合适的投资标的，加快落实公司兼并与重组；持续提升企业内部管理，增强精细化管理水平，提高公司的盈利能力；进一步开拓国内外目标市场，加大市场占有率。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042300009924.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429451069","title":"诺思格：股东减持主要受法律法规及公司IPO时承诺限制","url":"https://stock-news.laohu8.com/highlight/detail?id=2429451069","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2429451069?lang=zh_cn&edition=full","pubTime":"2024-04-22 18:02","pubTimestamp":1713780134,"startTime":"0","endTime":"0","summary":"证券之星消息，诺思格(301333)04月22日在投资者关系平台上答复投资者关心的问题。投资者：请问破发了大股东还能继续减持嘛诺思格董秘：尊敬的投资者您好！股东减持主要受法律法规及公司IPO时承诺限制。在破发情况下，根据当前法规和IPO时承诺，控股股东及作出减持价格承诺的股东减持价不得低于发行价，基金股东无此减持价格限制。感谢您的关注！以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042200021438.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2429867999","title":"诺思格(301333.SZ)发布一季度业绩，净利润2304.89万元，下降19.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2429867999","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2429867999?lang=zh_cn&edition=full","pubTime":"2024-04-21 15:57","pubTimestamp":1713686220,"startTime":"0","endTime":"0","summary":"诺思格(301333.SZ)发布2024年第一季度报告，该公司营业收入为1.77亿元，同比增长10.19%。归属于上市公司股东的净利润为2304.89万元，同比减少19.95%。归属于上市公司股东的扣除非经常性损益的净利润为1656.24万元，同比减少18.42%。基本每股收益为0.24元。\n\n股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……送给你>>\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-21/doc-inasqtfv2030257.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-04-21/doc-inasqtfv2030257.shtml","is_publish_highlight":false,"gpt_icon":0},{"id":"2412117187","title":"诺思格(301333.SZ)拟参设中金诺思格盛和(北京) 布局医疗健康行业","url":"https://stock-news.laohu8.com/highlight/detail?id=2412117187","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2412117187?lang=zh_cn&edition=full","pubTime":"2024-02-19 20:02","pubTimestamp":1708344120,"startTime":"0","endTime":"0","summary":"诺思格公告，公司拟与中金资本共同投资设立产业基金中金诺思格盛和(北京)合伙企业(暂定名)，该基金将专注投资于早中期生物医药创新及医疗器械公司等医疗健康行业。产业基金目标认缴资金规模不低于5亿元，初始认缴规模3.15亿元。公告称，本次对外投资有利于公司建立有竞争力的上下游产业链生态，助力公司实现外延式拓展，有利于公司长期稳健发展。股市回暖，抄底炒股先开户！智能定投、条件单、个股雷达……","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-19/doc-inaiqssy7802593.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2024-02-19/doc-inaiqssy7802593.shtml","is_publish_highlight":false,"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2022-08-02","address":"北京市通州区经济开发区东区创益西路518号","stockEarnings":[{"period":"1week","weight":-0.0633},{"period":"1month","weight":-0.1834},{"period":"3month","weight":-0.0955},{"period":"6month","weight":-0.4204},{"period":"1year","weight":-0.3038},{"period":"ytd","weight":-0.3212}],"companyName":"诺思格(北京)医药科技股份有限公司","boardCode":"AI0073","perCapita":"8170股","boardName":"研究和试验发展","registeredCapital":"9600万元","compareEarnings":[{"period":"1week","weight":-0.0002},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.1005},{"period":"6month","weight":0.0326},{"period":"1year","weight":-0.0435},{"period":"ytd","weight":0.0602}],"survey":"　　诺思格(北京)医药科技股份有限公司主营业务是为全球的医药企业和科研机构提供综合的药物临床研发全流程一体化服务。主要产品及服务是临床试验运营服务（“CO服务”）、临床试验现场管理服务（“SMO服务”）、生物样本检测服务（“BA服务”）、数据管理与统计分析服务（“DM/ST服务”）、临床试验咨询服务、临床药理学服务（“CP服务”）。公司荣获苏州市服务业创新型示范企业、南京市2018年度高新技术企业、苏州市服务业创新型示范企业。","serverTime":1716076754380,"listedPrice":78.88,"stockholders":"6943人(较上一季度增加46.17%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺思格(301333)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺思格(301333)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺思格,301333,诺思格股票,诺思格股票老虎,诺思格股票老虎国际,诺思格行情,诺思格股票行情,诺思格股价,诺思格股市,诺思格股票价格,诺思格股票交易,诺思格股票购买,诺思格股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺思格(301333)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺思格(301333)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}